STOCK TITAN

Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced it will report its Q2 financial results for the period ending June 30, 2022, on July 28, 2022, before U.S. markets open. A conference call will follow at 8:30 am ET to discuss the results and future expectations. Registered participants can access the call through a dedicated link. Alnylam, a leader in RNA interference therapeutics, continues to innovate with a pipeline of late-stage candidates aimed at addressing unmet medical needs.

Positive
  • Company plans to announce Q2 financial results, indicating ongoing business activity.
  • Will provide a future outlook during the conference call, likely to offer insights into strategic direction.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.

Management will provide an update on the Company and discuss second quarter 2022 results as well as expectations for the future via conference call on Thursday, July 28, 2022 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BId099ca291c69486ea91a87453136e78a. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals report its Q2 2022 earnings?

Alnylam Pharmaceuticals will report its Q2 2022 earnings on July 28, 2022.

What time is Alnylam's conference call for Q2 2022 results?

The conference call for Alnylam's Q2 2022 results will be held at 8:30 am ET on July 28, 2022.

Where can I find the live audio webcast of Alnylam's Q2 2022 earnings call?

The live audio webcast of Alnylam's Q2 2022 earnings call will be available on the Investors section of the company's website.

What is the significance of Alnylam's upcoming earnings release?

The upcoming earnings release will provide insight into Alnylam's financial performance and future expectations, which could impact its stock price.

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

ALNY Rankings

ALNY Latest News

ALNY Stock Data

30.98B
128.18M
0.43%
98.2%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE